Dehydrated Human Amnion Chorion Membrane (dHACM) vs. Control in the Treatment of Partial Thickness Burns.

Not Applicable

Terminated

• Conditions: Treatment of Partial Thickness Burns
• Interventions: Other: Dehydrated Human Amnion/Chorion Membrane; Device: Mepilex Ag

• Registration Number: NCT02765737
• Lead Sponsor: MiMedx Group, Inc.

Brief Summary

Multicenter, prospective, randomized, controlled feasibility trial to determine the safety and effectiveness of Dehydrated Human Amnion Chorion Membrane (dHACM) plus Control as compared to Control alone for the treatment of second degree burns (partial thickness burns) as assessed by time to healing and scarring

Detailed Description

Multicenter, prospective, randomized, controlled feasibility trial to determine the safety and effectiveness of Dehydrated Human Amnion Chorion Membrane (dHACM) plus Control as compared to Control alone for the treatment of second degree burns as assessed by time to healing and scarring

Study Timeline

• Study Start: 2016-04
• Study First Submitted: 2016-05-05
• Study First Submitted QC: 2016-05-06
• Study First Posted: 2016-05-09
• Primary Completion: 2019-01
• Study Completion: 2019-01
• Status Verified: 2020-11
• Last Update Submitted: 2022-05-10
• Last Update Posted: 2022-05-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

ll patients enrolled must meet all the following criteria:

1. Patient with burn injury that meets all of the following requirements:

   1. Occurred within the last 48 hours
   2. Wound is thermal in nature
   3. Partial-thickness burn (burn extends through the epidermis and may penetrate into the dermis)
   4. Total body surface area (TBSA) of burn(s) is 2-20% for all subjects
   5. Burn area(s) located on smooth, flat surface
   6. 2 burn areas, each with a minimum size of 16cm2 (burn areas may be two separate burns or within one large burn, see Section 9.4.2)

2. Age ≥ 12 months and ≤ 70 years

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded:

1. Burns meeting any of the following criteria:

   1. Mechanism of injury was electrical, radiation, chemical or frostbite

   2. Wound is larger than 200 cm2

   3. Clinically infected burn (as judged by the investigator)

   4. Previous or planned treatment of the Burn Area(s) with any of the following:

      • Biological Skin Substitutes (including Apligraf®, Dermagraft®, etc.)

2. Patient criteria that will make patient ineligible for enrollment:

   1. Ventilator dependence
   2. Active malignant disease or patient is less than 1 year disease-free
   3. Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days
   4. Auto-immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV)
   5. Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator
   6. Presence of any condition that is likely to compromise healing in the judgment of the Investigator
   7. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)
   8. Patient has been on any investigational drug(s) or therapeutic device(s) in the last 30 days or any previous enrollment in this study

3. Allergy or known sensitivity to any of the following:

   1. Aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate

   2. Silver

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 2	Mepilex Ag	Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
Group 2	Dehydrated Human Amnion/Chorion Membrane	Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
Group 1	Mepilex Ag	Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
Group 1	Dehydrated Human Amnion/Chorion Membrane	Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B

Primary Outcome Measures

Name	Time	Method
Freedom from Scarring	3 Months	Vancouver Scar Scale: consists of four variables: pliability, vascularity, height (thickness), and pigmentation. Each variable has four to six possible scores. A total score ranges from 0 to 14, whereby a score of 0 reflects normal skin.
Healing Rate	3 weeks	95% epitheliazation as assesses by the investigator

Secondary Outcome Measures

Name	Time	Method
Reduction in pain	3 weeks	Visual Analog Scale or FLACC Behavioral Pain Assessment Scale:VAS-No pain on left of line, worst pain imaginable on the right of line; FLACC- 0-2, (0 being least uncomfortable to 2 which is very uncomfortable)

Trial Locations

Locations (6)

Bruce Cairns Surgery Burn Center; 🇺🇸 Chapel Hill, North Carolina, United States

Arizona Burn Center; 🇺🇸 Phoenix, Arizona, United States

University of San Diego Nedical Center; 🇺🇸 San Diego, California, United States

Keck School of Medicine; 🇺🇸 Los Angeles, California, United States

St Elizabeth Reg Med Center; 🇺🇸 Lincoln, Nebraska, United States

Drexel University; 🇺🇸 Philadelphia, Pennsylvania, United States